View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
October 24, 2017

Bristol-Myers Squibb and Incyte are leading the clinical development of emerging checkpoint modulators

GlobalData analysts have identified 18 emerging immune checkpoint targets that are currently in clinical development.

GlobalData analysts have identified 18 emerging immune checkpoint targets that are currently in clinical development. When looking at the cumulative number of clinical trials with immune checkpoint modulators from 2010 to Q2 2017, two companies, Bristol-Myers Squibb and Incyte, stand out as the main developers of emerging immune checkpoint modulators.

In Q2 2017, Bristol-Myers Squibb’s emerging checkpoint modulators were being explored in 33 clinical trials in Phase I to III, based on the clinical assessment of eight different drugs. Each of these eight products are associated with different emerging immune checkpoint targets, including indoleamine 2, 3-dioxygenase 1 (IDO1) and lymphocyte-activation gene 3 (LAG3) targets.

Based on the same cut-off point, Incyte’s emerging checkpoint modulators were evaluated in 26 clinical trials. In this period, Incyte developed fewer drugs than Bristol-Myers Squibb, with only three drugs covering three different targets. GlobalData’s analysis reveals that this high trial number is associated with the extensive clinical development of Incyte’s IDO1 inhibitor, epacadostat, across tumor types.

Related reports

GlobalData (2017). PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities, August 2017, GDHC009PFR.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena